DURHAM, N.C. - Chimerix (NASDAQ:CMRX), in collaboration with the Rapidly Emerging Antiviral Drug Development Initiative at the University of North Carolina at Chapel Hill, announced that preclinical data from the Company's CMX521 program will be featured in a late-breaking oral presentation session at the International Conference on Antiviral Research (ICAR) on Wednesday, March 23, 2022 from 12:15 - 1:00 pm PT.

'While we focus on the advancement of our oncology pipeline and progress toward a TEMBEXA procurement agreement with BARDA, this collaboration with READDI allows us to efficiently evaluate our antiviral library to identify molecules that might have value to patients,' said Mike Sherman, Chief Executive Officer of Chimerix. 'The joint effort between the research teams at both Chimerix and READDI has led to these very promising early results in an animal model that we believe supports rapid advancement of CMX521 to clinical proof-of-concept against SARS-CoV-2 where there remains a need for novel therapies with improved efficacy, safety and/or resistance profiles. This agent is particularly interesting in that it has demonstrated an attractive safety profile in a prior Phase 1 dose escalation trial in healthy volunteers.'

'These compelling data encourage us to further investigate the potential of CMX521 as a prophylactic and as a therapeutic for SARS-CoV-2 infection,' said John Bamforth, PhD of READDI and Director of Eshelman Institute for Innovation at the UNC Eshelman School of Pharmacy. 'We are very excited about these data and also look forward to READDI's ongoing mission to identify novel antivirals active against entire families of viruses, including coronaviruses, flaviviruses and alphaviruses.'

The presentation is titled, 'The nucleoside analog antiviral CMX521 inhibits SARS-CoV-2 in human airway epithelial cell cultures and exhibits prophylactic and therapeutic efficacy against respiratory disease in a mouse model of SARS-CoV-2 infection', highlights in vitro activity and in vivo efficacy of this novel compound. In vitro, CMX521 was shown to inhibit SARS-CoV-2 replication in primary human airway epithelial cells with an average EC50 of 0.9-microM. In vivo, studies were performed in an animal model used during development of a different antiviral therapy which has obtained Emergency Use Authorization for SARS-CoV-2 in the United States. The animal studies randomized mice to CMX521 or placebo at various times relative to viral infection to explore the potential for prophylactic and therapeutic efficacy.

Monotherapy prophylactic administration of aerosol CMX521 every eight hours starting eight hours prior to infection reduced average viral titers in lung on day four post-infection by 3.62 log10 (>99.9% reduction) and prevented weight loss/clinical progression versus placebo. Antiviral efficacy was also demonstrated with monotherapy treatment when CMX521 was initiated post-infection. CMX521 treatment significantly reduced SARS-CoV-2 in the lung (Kruskal-Wallis p

(C) 2022 Electronic News Publishing, source ENP Newswire